Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes.

Literature DB >> 8124665

Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes.

U von Eitzen¹, D Meier-Tackmann, D P Agarwal, H W Goedde.

Abstract

In in vitro studies, no turnover of aldophosphamide and mafosfamide was observed with the tumor-specific aldehyde dehydrogenase 3 isozyme (ALDH3) isolated from human stomach mucosa as well as from lung (A549) and pharynx (UMSCC2) carcinoma cell lines. Only the human liver cytosolic ALDH preparation (ALDH1) showed any significant oxidation of aldophosphamide and mafosfamide.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1994 PMID： 8124665 DOI： 10.1016/0304-3835(94)90132-5

Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679

Keyword Cloud
Cited

12 in total

1. Discovery of a novel class of covalent inhibitor for aldehyde dehydrogenases.

Authors: May Khanna; Che-Hong Chen; Ann Kimble-Hill; Bibek Parajuli; Samantha Perez-Miller; Sulochanadevi Baskaran; Jeewon Kim; Karl Dria; Vasilis Vasiliou; Daria Mochly-Rosen; Thomas D Hurley
Journal: J Biol Chem Date: 2011-10-21 Impact factor: 5.157

2. The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies.

Authors: Duan Wang; Linhao Li; Hui Yang; Stephen S Ferguson; Maria R Baer; Ronald B Gartenhaus; Hongbing Wang
Journal: Blood Date: 2012-11-16 Impact factor: 22.113

Review 3. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.

Authors: N A Helsby; M Yong; M van Kan; J R de Zoysa; K E Burns
Journal: Br J Clin Pharmacol Date: 2019-07-22 Impact factor: 4.335

4. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.

Authors: Ola Awad; Jason T Yustein; Preeti Shah; Naheed Gul; Varalakshmi Katuri; Alison O'Neill; Yali Kong; Milton L Brown; Jeffrey A Toretsky; David M Loeb
Journal: PLoS One Date: 2010-11-11 Impact factor: 3.240

5. Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.

Authors: Duan Wang; Hongbing Wang
Journal: Acta Pharm Sin B Date: 2012-04-01 Impact factor: 11.413

6. A point mutation produced a class 3 aldehyde dehydrogenase with increased protective ability against the killing effect of cyclophosphamide.

Authors: Kwok Ki Ho; Abhijit Mukhopadhyay; Yi Feng Li; Soma Mukhopadhyay; Henry Weiner
Journal: Biochem Pharmacol Date: 2008-07-04 Impact factor: 5.858

Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes.

1. Discovery of a novel class of covalent inhibitor for aldehyde dehydrogenases.

2. The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies.

Review 3. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.

4. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.

5. Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.

6. A point mutation produced a class 3 aldehyde dehydrogenase with increased protective ability against the killing effect of cyclophosphamide.

7. The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung Cancer.

Review 8. Clinical pharmacokinetics of cyclophosphamide.

9. Development of selective inhibitors for aldehyde dehydrogenases based on substituted indole-2,3-diones.

10. Cancer stem cells of differentiated B-cell malignancies: models and consequences.